Alwan, Julandi2026-02-162026-02-162025https://hdl.handle.net/10566/21963Ameloblastoma, the most common odontogenic tumour in Sub-Saharan Africa, poses considerable clinical challenges due to its locally aggressive behaviour and high recurrence rate. Recent molecular advances have identified BRAF V600E mutations as pivotal in tumorigenesis, alongside mutations in other MAPK pathway genes and SMO mutations in the hedgehog pathway. These discoveries suggest potential targets for emerging therapies, including BRAF and MEK inhibitors, which have demonstrated efficacy in preclinical studies for limiting tumour growth. Standard treatment involves disfiguring surgical excision, with an emphasis on wide local resection to minimize recurrence, though challenges persist in achieving clear margins due to its infiltrative nature. Alternative therapies targeting specific mutations offer promising avenues for less invasive management, pending further clinical validation to establish their efficacy and safety.enAmeloblastomaBRAF mutationHistopathologyTherapeutic targetsMolecular biologyThesis